PE20130640A1 - Compuestos heterociclicos, su preparacion y su aplicacion terapeutica - Google Patents

Compuestos heterociclicos, su preparacion y su aplicacion terapeutica

Info

Publication number
PE20130640A1
PE20130640A1 PE2012002466A PE2012002466A PE20130640A1 PE 20130640 A1 PE20130640 A1 PE 20130640A1 PE 2012002466 A PE2012002466 A PE 2012002466A PE 2012002466 A PE2012002466 A PE 2012002466A PE 20130640 A1 PE20130640 A1 PE 20130640A1
Authority
PE
Peru
Prior art keywords
pyridin
compounds
triazolo
chloro
phenol
Prior art date
Application number
PE2012002466A
Other languages
English (en)
Inventor
David Middlemiss
Caroline Leriche
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of PE20130640A1 publication Critical patent/PE20130640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE A ES FENILO; B ES FENILO, PIRIDINA O PIRIMIDINA; R1 Y R2 SON CADA UNO H, OH O HALOGENO; R3, R4 Y R5 SON CADA UNO H, O-ALQUILO(C1-C6), OH, HETEROCICLOALQUIL-(CH2)n-OH, ENTRE OTROS, EN DONDE n ES DE 1 A 3; R6 ES H, O-ALQUILO(C1-C6) O ALQUILO(C1-C6); X ES N O C; Y ES CH O UN ENLACE COVALENTE. SON COMPUESTOS PREFERIDOS: 4-CLORO-3-[2-(PIRIDIN-3-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL; 4-CLORO-3-[2-(PIRIMIDIN-5-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL; 4-CLORO-3-[2-(5-HIDROXIMETIL-PIRIDIN-3-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA Src SIENDO UTILES EN EL TRATAMIENTO DE EDEMA RETINIANO, DEGENERACION MACULAR, RETINOPATIA DIABETICA
PE2012002466A 2010-06-22 2011-06-22 Compuestos heterociclicos, su preparacion y su aplicacion terapeutica PE20130640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305665 2010-06-22

Publications (1)

Publication Number Publication Date
PE20130640A1 true PE20130640A1 (es) 2013-03-30

Family

ID=43033247

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002466A PE20130640A1 (es) 2010-06-22 2011-06-22 Compuestos heterociclicos, su preparacion y su aplicacion terapeutica

Country Status (27)

Country Link
US (1) US20130123271A1 (es)
EP (1) EP2585439A1 (es)
JP (1) JP2013533237A (es)
KR (1) KR20130116070A (es)
CN (1) CN103140480A (es)
AR (1) AR081960A1 (es)
AU (1) AU2011268938A1 (es)
BR (1) BR112012032721A2 (es)
CA (1) CA2803496A1 (es)
CL (1) CL2012003637A1 (es)
CO (1) CO6660505A2 (es)
CR (1) CR20120653A (es)
DO (1) DOP2012000317A (es)
EA (1) EA201291329A1 (es)
EC (1) ECSP12012354A (es)
GT (1) GT201200345A (es)
IL (1) IL223721A0 (es)
MA (1) MA34384B1 (es)
MX (1) MX2012015305A (es)
NI (1) NI201200193A (es)
NZ (1) NZ605022A (es)
PE (1) PE20130640A1 (es)
SG (1) SG186424A1 (es)
TN (1) TN2012000610A1 (es)
TW (1) TW201204723A (es)
UY (1) UY33461A (es)
WO (1) WO2011161159A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
US20160264568A1 (en) * 2013-06-07 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
WO2014198594A1 (en) * 2013-06-10 2014-12-18 Bayer Pharma Aktiengesellschaft Novel compounds for the treatment of cancer
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
EA201791304A1 (ru) 2014-12-24 2017-12-29 Джилид Сайэнс, Инк. Производные изохинолина для лечения вич
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
EP3440074A1 (en) 2016-04-08 2019-02-13 Baylor College of Medicine Small molecule regulators of steroid receptor coactivators and methods of use thereof
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
WO2021254464A1 (zh) * 2020-06-19 2021-12-23 南京红云生物科技有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
MXPA02003140A (es) 1999-11-22 2002-09-30 Warner Lambert Co Quinazolinas y su uso para la inhibicion de las enzimas cinasa dependientes del ciclin.
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1680122A1 (en) 2003-10-16 2006-07-19 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for the treatment of cancer
EP1809614B1 (en) 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
WO2006024034A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2006227628A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
US7906522B2 (en) * 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
MX2007008848A (es) 2005-06-08 2008-04-16 Targegen Inc Metodos y composiciones para el tratamiento de desordenes oculares.
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US20100216791A1 (en) 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
EP2125755A2 (en) 2006-12-22 2009-12-02 Novartis Ag Quinazolines for pdk1 inhibition
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100311965A1 (en) 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基***并吡啶，其組合物及使用其之治療方法
PE20120424A1 (es) 2008-12-29 2012-05-04 Fovea Pharmaceuticals Compuestos de quinazolina sustituidos
EA201101188A1 (ru) * 2009-02-13 2012-04-30 Фовеа Фармасьютикалз [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы

Also Published As

Publication number Publication date
CN103140480A (zh) 2013-06-05
MX2012015305A (es) 2013-05-30
MA34384B1 (fr) 2013-07-03
US20130123271A1 (en) 2013-05-16
CO6660505A2 (es) 2013-04-30
AR081960A1 (es) 2012-10-31
EA201291329A1 (ru) 2013-05-30
IL223721A0 (en) 2013-03-05
TN2012000610A1 (en) 2014-04-01
GT201200345A (es) 2014-01-24
ECSP12012354A (es) 2013-01-31
CL2012003637A1 (es) 2013-07-05
TW201204723A (en) 2012-02-01
BR112012032721A2 (pt) 2016-11-29
KR20130116070A (ko) 2013-10-22
SG186424A1 (en) 2013-01-30
WO2011161159A1 (en) 2011-12-29
CR20120653A (es) 2013-04-03
CA2803496A1 (en) 2011-12-29
EP2585439A1 (en) 2013-05-01
DOP2012000317A (es) 2013-04-15
UY33461A (es) 2012-01-31
NZ605022A (en) 2013-12-20
NI201200193A (es) 2013-05-13
JP2013533237A (ja) 2013-08-22
AU2011268938A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
PE20130640A1 (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
PE20080263A1 (es) Compuestos de pirrolo-pirimidina y sus usos
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
HRP20201165T1 (hr) Uporaba inhibitora ccr3
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
TN2013000275A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
PE20140408A1 (es) Derivados espiro-oxindol como antagonistas de mdm2
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
PE20150623A1 (es) Moduladores de la ruta del complemento y usos de los mismos
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
MX2013014007A (es) [1,3] oxazinas.
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PE20170003A1 (es) Compuestos heterociclicos y usos de los mismos
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak

Legal Events

Date Code Title Description
FC Refusal